Amivantamab 350mg/7mL
| Product Overview | |
| Generic Name | Amivantamab 350mg/7mL |
| Brand Name(s) | RYBREVANT® |
| Form | Originator Brand ONLY, solution for IV infusion, single-dose vial |
| Strength | 350 mg/7 mL (50 mg/mL) |
| Therapeutic Class | Targeted therapy (EGFR–MET bispecific antibody) |
| ATC Code | L01FX18 |
| Manufacturing & Regulatory | |
| Manufacturer | Janssen Biotech |
| Country | USA |
| GMP Compliance | WHO-GMP |
| Free Sale Certificate | Potentially available depending on the exporting jurisdiction |
| Logistics & Export | |
| MOQ | 10 |
| Shelf Life | 24 months at 2–8°C |
| Storage | Refrigerate at 2 °C to 8 °C |
| Incoterms | Ex-Works |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes, typically available as lot/batch CoA |
| CTD Summary | CTD is proprietary |
Description
No-Biosimilar available as molecule still under patent protection. Indicated to treat advanced NSCLC with specific EGFR alterations.
